nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoversetamide—Hyperglycaemia—Epirubicin—bone cancer	0.00193	0.00193	CcSEcCtD
Gadoversetamide—Epistaxis—Methotrexate—bone cancer	0.00192	0.00192	CcSEcCtD
Gadoversetamide—Pneumonia—Epirubicin—bone cancer	0.00192	0.00192	CcSEcCtD
Gadoversetamide—Body temperature increased—Cisplatin—bone cancer	0.00187	0.00187	CcSEcCtD
Gadoversetamide—Conjunctivitis—Epirubicin—bone cancer	0.00185	0.00185	CcSEcCtD
Gadoversetamide—Urinary tract infection—Epirubicin—bone cancer	0.00185	0.00185	CcSEcCtD
Gadoversetamide—Dysuria—Doxorubicin—bone cancer	0.00185	0.00185	CcSEcCtD
Gadoversetamide—Haemoglobin—Methotrexate—bone cancer	0.00184	0.00184	CcSEcCtD
Gadoversetamide—Haemorrhage—Methotrexate—bone cancer	0.00183	0.00183	CcSEcCtD
Gadoversetamide—Haematuria—Epirubicin—bone cancer	0.00182	0.00182	CcSEcCtD
Gadoversetamide—Pharyngitis—Methotrexate—bone cancer	0.00182	0.00182	CcSEcCtD
Gadoversetamide—Urinary tract disorder—Methotrexate—bone cancer	0.00181	0.00181	CcSEcCtD
Gadoversetamide—Epistaxis—Epirubicin—bone cancer	0.0018	0.0018	CcSEcCtD
Gadoversetamide—Urethral disorder—Methotrexate—bone cancer	0.00179	0.00179	CcSEcCtD
Gadoversetamide—Sinusitis—Epirubicin—bone cancer	0.00179	0.00179	CcSEcCtD
Gadoversetamide—Hyperglycaemia—Doxorubicin—bone cancer	0.00179	0.00179	CcSEcCtD
Gadoversetamide—Pneumonia—Doxorubicin—bone cancer	0.00178	0.00178	CcSEcCtD
Gadoversetamide—Hypersensitivity—Cisplatin—bone cancer	0.00175	0.00175	CcSEcCtD
Gadoversetamide—Erythema multiforme—Methotrexate—bone cancer	0.00173	0.00173	CcSEcCtD
Gadoversetamide—Haemoglobin—Epirubicin—bone cancer	0.00172	0.00172	CcSEcCtD
Gadoversetamide—Rhinitis—Epirubicin—bone cancer	0.00172	0.00172	CcSEcCtD
Gadoversetamide—Urinary tract infection—Doxorubicin—bone cancer	0.00172	0.00172	CcSEcCtD
Gadoversetamide—Conjunctivitis—Doxorubicin—bone cancer	0.00172	0.00172	CcSEcCtD
Gadoversetamide—Haemorrhage—Epirubicin—bone cancer	0.00171	0.00171	CcSEcCtD
Gadoversetamide—Eye disorder—Methotrexate—bone cancer	0.00171	0.00171	CcSEcCtD
Gadoversetamide—Tinnitus—Methotrexate—bone cancer	0.00171	0.00171	CcSEcCtD
Gadoversetamide—Hypoaesthesia—Epirubicin—bone cancer	0.0017	0.0017	CcSEcCtD
Gadoversetamide—Asthenia—Cisplatin—bone cancer	0.0017	0.0017	CcSEcCtD
Gadoversetamide—Pharyngitis—Epirubicin—bone cancer	0.0017	0.0017	CcSEcCtD
Gadoversetamide—Cardiac disorder—Methotrexate—bone cancer	0.0017	0.0017	CcSEcCtD
Gadoversetamide—Urinary tract disorder—Epirubicin—bone cancer	0.00169	0.00169	CcSEcCtD
Gadoversetamide—Oedema peripheral—Epirubicin—bone cancer	0.00169	0.00169	CcSEcCtD
Gadoversetamide—Haematuria—Doxorubicin—bone cancer	0.00168	0.00168	CcSEcCtD
Gadoversetamide—Urethral disorder—Epirubicin—bone cancer	0.00168	0.00168	CcSEcCtD
Gadoversetamide—Epistaxis—Doxorubicin—bone cancer	0.00166	0.00166	CcSEcCtD
Gadoversetamide—Angiopathy—Methotrexate—bone cancer	0.00166	0.00166	CcSEcCtD
Gadoversetamide—Sinusitis—Doxorubicin—bone cancer	0.00166	0.00166	CcSEcCtD
Gadoversetamide—Immune system disorder—Methotrexate—bone cancer	0.00165	0.00165	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Methotrexate—bone cancer	0.00165	0.00165	CcSEcCtD
Gadoversetamide—Chills—Methotrexate—bone cancer	0.00164	0.00164	CcSEcCtD
Gadoversetamide—Diarrhoea—Cisplatin—bone cancer	0.00162	0.00162	CcSEcCtD
Gadoversetamide—Erythema multiforme—Epirubicin—bone cancer	0.00162	0.00162	CcSEcCtD
Gadoversetamide—Mental disorder—Methotrexate—bone cancer	0.0016	0.0016	CcSEcCtD
Gadoversetamide—Eye disorder—Epirubicin—bone cancer	0.0016	0.0016	CcSEcCtD
Gadoversetamide—Tinnitus—Epirubicin—bone cancer	0.0016	0.0016	CcSEcCtD
Gadoversetamide—Erythema—Methotrexate—bone cancer	0.00159	0.00159	CcSEcCtD
Gadoversetamide—Malnutrition—Methotrexate—bone cancer	0.00159	0.00159	CcSEcCtD
Gadoversetamide—Haemoglobin—Doxorubicin—bone cancer	0.00159	0.00159	CcSEcCtD
Gadoversetamide—Flushing—Epirubicin—bone cancer	0.00159	0.00159	CcSEcCtD
Gadoversetamide—Cardiac disorder—Epirubicin—bone cancer	0.00159	0.00159	CcSEcCtD
Gadoversetamide—Rhinitis—Doxorubicin—bone cancer	0.00159	0.00159	CcSEcCtD
Gadoversetamide—Haemorrhage—Doxorubicin—bone cancer	0.00158	0.00158	CcSEcCtD
Gadoversetamide—Hypoaesthesia—Doxorubicin—bone cancer	0.00158	0.00158	CcSEcCtD
Gadoversetamide—Pharyngitis—Doxorubicin—bone cancer	0.00157	0.00157	CcSEcCtD
Gadoversetamide—Urinary tract disorder—Doxorubicin—bone cancer	0.00156	0.00156	CcSEcCtD
Gadoversetamide—Oedema peripheral—Doxorubicin—bone cancer	0.00156	0.00156	CcSEcCtD
Gadoversetamide—Dysgeusia—Methotrexate—bone cancer	0.00156	0.00156	CcSEcCtD
Gadoversetamide—Angiopathy—Epirubicin—bone cancer	0.00155	0.00155	CcSEcCtD
Gadoversetamide—Urethral disorder—Doxorubicin—bone cancer	0.00155	0.00155	CcSEcCtD
Gadoversetamide—Immune system disorder—Epirubicin—bone cancer	0.00155	0.00155	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Epirubicin—bone cancer	0.00154	0.00154	CcSEcCtD
Gadoversetamide—Back pain—Methotrexate—bone cancer	0.00154	0.00154	CcSEcCtD
Gadoversetamide—Chills—Epirubicin—bone cancer	0.00154	0.00154	CcSEcCtD
Gadoversetamide—Arrhythmia—Epirubicin—bone cancer	0.00153	0.00153	CcSEcCtD
Gadoversetamide—Vomiting—Cisplatin—bone cancer	0.00151	0.00151	CcSEcCtD
Gadoversetamide—Vision blurred—Methotrexate—bone cancer	0.0015	0.0015	CcSEcCtD
Gadoversetamide—Mental disorder—Epirubicin—bone cancer	0.0015	0.0015	CcSEcCtD
Gadoversetamide—Erythema multiforme—Doxorubicin—bone cancer	0.0015	0.0015	CcSEcCtD
Gadoversetamide—Rash—Cisplatin—bone cancer	0.00149	0.00149	CcSEcCtD
Gadoversetamide—Dermatitis—Cisplatin—bone cancer	0.00149	0.00149	CcSEcCtD
Gadoversetamide—Erythema—Epirubicin—bone cancer	0.00149	0.00149	CcSEcCtD
Gadoversetamide—Malnutrition—Epirubicin—bone cancer	0.00149	0.00149	CcSEcCtD
Gadoversetamide—Eye disorder—Doxorubicin—bone cancer	0.00148	0.00148	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Methotrexate—bone cancer	0.00148	0.00148	CcSEcCtD
Gadoversetamide—Tinnitus—Doxorubicin—bone cancer	0.00148	0.00148	CcSEcCtD
Gadoversetamide—Cardiac disorder—Doxorubicin—bone cancer	0.00147	0.00147	CcSEcCtD
Gadoversetamide—Flushing—Doxorubicin—bone cancer	0.00147	0.00147	CcSEcCtD
Gadoversetamide—Flatulence—Epirubicin—bone cancer	0.00147	0.00147	CcSEcCtD
Gadoversetamide—Tension—Epirubicin—bone cancer	0.00146	0.00146	CcSEcCtD
Gadoversetamide—Dysgeusia—Epirubicin—bone cancer	0.00146	0.00146	CcSEcCtD
Gadoversetamide—Nervousness—Epirubicin—bone cancer	0.00145	0.00145	CcSEcCtD
Gadoversetamide—Back pain—Epirubicin—bone cancer	0.00144	0.00144	CcSEcCtD
Gadoversetamide—Angiopathy—Doxorubicin—bone cancer	0.00144	0.00144	CcSEcCtD
Gadoversetamide—Malaise—Methotrexate—bone cancer	0.00144	0.00144	CcSEcCtD
Gadoversetamide—Muscle spasms—Epirubicin—bone cancer	0.00143	0.00143	CcSEcCtD
Gadoversetamide—Immune system disorder—Doxorubicin—bone cancer	0.00143	0.00143	CcSEcCtD
Gadoversetamide—Vertigo—Methotrexate—bone cancer	0.00143	0.00143	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Doxorubicin—bone cancer	0.00143	0.00143	CcSEcCtD
Gadoversetamide—Chills—Doxorubicin—bone cancer	0.00142	0.00142	CcSEcCtD
Gadoversetamide—Arrhythmia—Doxorubicin—bone cancer	0.00142	0.00142	CcSEcCtD
Gadoversetamide—Nausea—Cisplatin—bone cancer	0.00141	0.00141	CcSEcCtD
Gadoversetamide—Vision blurred—Epirubicin—bone cancer	0.0014	0.0014	CcSEcCtD
Gadoversetamide—Cough—Methotrexate—bone cancer	0.00139	0.00139	CcSEcCtD
Gadoversetamide—Mental disorder—Doxorubicin—bone cancer	0.00139	0.00139	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Epirubicin—bone cancer	0.00138	0.00138	CcSEcCtD
Gadoversetamide—Convulsion—Methotrexate—bone cancer	0.00138	0.00138	CcSEcCtD
Gadoversetamide—Malnutrition—Doxorubicin—bone cancer	0.00138	0.00138	CcSEcCtD
Gadoversetamide—Erythema—Doxorubicin—bone cancer	0.00138	0.00138	CcSEcCtD
Gadoversetamide—Agitation—Epirubicin—bone cancer	0.00137	0.00137	CcSEcCtD
Gadoversetamide—Flatulence—Doxorubicin—bone cancer	0.00136	0.00136	CcSEcCtD
Gadoversetamide—Chest pain—Methotrexate—bone cancer	0.00136	0.00136	CcSEcCtD
Gadoversetamide—Myalgia—Methotrexate—bone cancer	0.00136	0.00136	CcSEcCtD
Gadoversetamide—Arthralgia—Methotrexate—bone cancer	0.00136	0.00136	CcSEcCtD
Gadoversetamide—Tension—Doxorubicin—bone cancer	0.00135	0.00135	CcSEcCtD
Gadoversetamide—Dysgeusia—Doxorubicin—bone cancer	0.00135	0.00135	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00135	0.00135	CcSEcCtD
Gadoversetamide—Malaise—Epirubicin—bone cancer	0.00134	0.00134	CcSEcCtD
Gadoversetamide—Discomfort—Methotrexate—bone cancer	0.00134	0.00134	CcSEcCtD
Gadoversetamide—Nervousness—Doxorubicin—bone cancer	0.00134	0.00134	CcSEcCtD
Gadoversetamide—Vertigo—Epirubicin—bone cancer	0.00134	0.00134	CcSEcCtD
Gadoversetamide—Syncope—Epirubicin—bone cancer	0.00134	0.00134	CcSEcCtD
Gadoversetamide—Back pain—Doxorubicin—bone cancer	0.00133	0.00133	CcSEcCtD
Gadoversetamide—Muscle spasms—Doxorubicin—bone cancer	0.00133	0.00133	CcSEcCtD
Gadoversetamide—Palpitations—Epirubicin—bone cancer	0.00132	0.00132	CcSEcCtD
Gadoversetamide—Confusional state—Methotrexate—bone cancer	0.00131	0.00131	CcSEcCtD
Gadoversetamide—Loss of consciousness—Epirubicin—bone cancer	0.00131	0.00131	CcSEcCtD
Gadoversetamide—Cough—Epirubicin—bone cancer	0.0013	0.0013	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Methotrexate—bone cancer	0.0013	0.0013	CcSEcCtD
Gadoversetamide—Vision blurred—Doxorubicin—bone cancer	0.0013	0.0013	CcSEcCtD
Gadoversetamide—Convulsion—Epirubicin—bone cancer	0.00129	0.00129	CcSEcCtD
Gadoversetamide—Hypertension—Epirubicin—bone cancer	0.00129	0.00129	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Doxorubicin—bone cancer	0.00128	0.00128	CcSEcCtD
Gadoversetamide—Nervous system disorder—Methotrexate—bone cancer	0.00127	0.00127	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Methotrexate—bone cancer	0.00127	0.00127	CcSEcCtD
Gadoversetamide—Chest pain—Epirubicin—bone cancer	0.00127	0.00127	CcSEcCtD
Gadoversetamide—Myalgia—Epirubicin—bone cancer	0.00127	0.00127	CcSEcCtD
Gadoversetamide—Arthralgia—Epirubicin—bone cancer	0.00127	0.00127	CcSEcCtD
Gadoversetamide—Agitation—Doxorubicin—bone cancer	0.00127	0.00127	CcSEcCtD
Gadoversetamide—Anxiety—Epirubicin—bone cancer	0.00126	0.00126	CcSEcCtD
Gadoversetamide—Skin disorder—Methotrexate—bone cancer	0.00126	0.00126	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00126	0.00126	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Methotrexate—bone cancer	0.00126	0.00126	CcSEcCtD
Gadoversetamide—Discomfort—Epirubicin—bone cancer	0.00125	0.00125	CcSEcCtD
Gadoversetamide—Malaise—Doxorubicin—bone cancer	0.00124	0.00124	CcSEcCtD
Gadoversetamide—Dry mouth—Epirubicin—bone cancer	0.00124	0.00124	CcSEcCtD
Gadoversetamide—Vertigo—Doxorubicin—bone cancer	0.00124	0.00124	CcSEcCtD
Gadoversetamide—Anorexia—Methotrexate—bone cancer	0.00124	0.00124	CcSEcCtD
Gadoversetamide—Syncope—Doxorubicin—bone cancer	0.00124	0.00124	CcSEcCtD
Gadoversetamide—Confusional state—Epirubicin—bone cancer	0.00123	0.00123	CcSEcCtD
Gadoversetamide—Palpitations—Doxorubicin—bone cancer	0.00122	0.00122	CcSEcCtD
Gadoversetamide—Oedema—Epirubicin—bone cancer	0.00122	0.00122	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Epirubicin—bone cancer	0.00122	0.00122	CcSEcCtD
Gadoversetamide—Hypotension—Methotrexate—bone cancer	0.00121	0.00121	CcSEcCtD
Gadoversetamide—Loss of consciousness—Doxorubicin—bone cancer	0.00121	0.00121	CcSEcCtD
Gadoversetamide—Cough—Doxorubicin—bone cancer	0.0012	0.0012	CcSEcCtD
Gadoversetamide—Shock—Epirubicin—bone cancer	0.0012	0.0012	CcSEcCtD
Gadoversetamide—Convulsion—Doxorubicin—bone cancer	0.00119	0.00119	CcSEcCtD
Gadoversetamide—Nervous system disorder—Epirubicin—bone cancer	0.00119	0.00119	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Epirubicin—bone cancer	0.00119	0.00119	CcSEcCtD
Gadoversetamide—Hypertension—Doxorubicin—bone cancer	0.00119	0.00119	CcSEcCtD
Gadoversetamide—Tachycardia—Epirubicin—bone cancer	0.00119	0.00119	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00118	0.00118	CcSEcCtD
Gadoversetamide—Skin disorder—Epirubicin—bone cancer	0.00118	0.00118	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Epirubicin—bone cancer	0.00118	0.00118	CcSEcCtD
Gadoversetamide—Insomnia—Methotrexate—bone cancer	0.00118	0.00118	CcSEcCtD
Gadoversetamide—Chest pain—Doxorubicin—bone cancer	0.00117	0.00117	CcSEcCtD
Gadoversetamide—Arthralgia—Doxorubicin—bone cancer	0.00117	0.00117	CcSEcCtD
Gadoversetamide—Myalgia—Doxorubicin—bone cancer	0.00117	0.00117	CcSEcCtD
Gadoversetamide—Anxiety—Doxorubicin—bone cancer	0.00117	0.00117	CcSEcCtD
Gadoversetamide—Paraesthesia—Methotrexate—bone cancer	0.00117	0.00117	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00117	0.00117	CcSEcCtD
Gadoversetamide—Discomfort—Doxorubicin—bone cancer	0.00116	0.00116	CcSEcCtD
Gadoversetamide—Anorexia—Epirubicin—bone cancer	0.00116	0.00116	CcSEcCtD
Gadoversetamide—Dyspnoea—Methotrexate—bone cancer	0.00116	0.00116	CcSEcCtD
Gadoversetamide—Somnolence—Methotrexate—bone cancer	0.00116	0.00116	CcSEcCtD
Gadoversetamide—Dry mouth—Doxorubicin—bone cancer	0.00115	0.00115	CcSEcCtD
Gadoversetamide—Dyspepsia—Methotrexate—bone cancer	0.00114	0.00114	CcSEcCtD
Gadoversetamide—Hypotension—Epirubicin—bone cancer	0.00114	0.00114	CcSEcCtD
Gadoversetamide—Confusional state—Doxorubicin—bone cancer	0.00113	0.00113	CcSEcCtD
Gadoversetamide—Decreased appetite—Methotrexate—bone cancer	0.00113	0.00113	CcSEcCtD
Gadoversetamide—Oedema—Doxorubicin—bone cancer	0.00113	0.00113	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Doxorubicin—bone cancer	0.00113	0.00113	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Methotrexate—bone cancer	0.00112	0.00112	CcSEcCtD
Gadoversetamide—Fatigue—Methotrexate—bone cancer	0.00112	0.00112	CcSEcCtD
Gadoversetamide—Pain—Methotrexate—bone cancer	0.00111	0.00111	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00111	0.00111	CcSEcCtD
Gadoversetamide—Shock—Doxorubicin—bone cancer	0.00111	0.00111	CcSEcCtD
Gadoversetamide—Nervous system disorder—Doxorubicin—bone cancer	0.0011	0.0011	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Doxorubicin—bone cancer	0.0011	0.0011	CcSEcCtD
Gadoversetamide—Insomnia—Epirubicin—bone cancer	0.0011	0.0011	CcSEcCtD
Gadoversetamide—Tachycardia—Doxorubicin—bone cancer	0.0011	0.0011	CcSEcCtD
Gadoversetamide—Skin disorder—Doxorubicin—bone cancer	0.00109	0.00109	CcSEcCtD
Gadoversetamide—Paraesthesia—Epirubicin—bone cancer	0.00109	0.00109	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Doxorubicin—bone cancer	0.00109	0.00109	CcSEcCtD
Gadoversetamide—Dyspnoea—Epirubicin—bone cancer	0.00108	0.00108	CcSEcCtD
Gadoversetamide—Somnolence—Epirubicin—bone cancer	0.00108	0.00108	CcSEcCtD
Gadoversetamide—Anorexia—Doxorubicin—bone cancer	0.00107	0.00107	CcSEcCtD
Gadoversetamide—Feeling abnormal—Methotrexate—bone cancer	0.00107	0.00107	CcSEcCtD
Gadoversetamide—Dyspepsia—Epirubicin—bone cancer	0.00107	0.00107	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Methotrexate—bone cancer	0.00106	0.00106	CcSEcCtD
Gadoversetamide—Decreased appetite—Epirubicin—bone cancer	0.00106	0.00106	CcSEcCtD
Gadoversetamide—Hypotension—Doxorubicin—bone cancer	0.00105	0.00105	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Epirubicin—bone cancer	0.00105	0.00105	CcSEcCtD
Gadoversetamide—Fatigue—Epirubicin—bone cancer	0.00105	0.00105	CcSEcCtD
Gadoversetamide—Constipation—Epirubicin—bone cancer	0.00104	0.00104	CcSEcCtD
Gadoversetamide—Pain—Epirubicin—bone cancer	0.00104	0.00104	CcSEcCtD
Gadoversetamide—Urticaria—Methotrexate—bone cancer	0.00103	0.00103	CcSEcCtD
Gadoversetamide—Abdominal pain—Methotrexate—bone cancer	0.00103	0.00103	CcSEcCtD
Gadoversetamide—Body temperature increased—Methotrexate—bone cancer	0.00103	0.00103	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.00103	0.00103	CcSEcCtD
Gadoversetamide—Insomnia—Doxorubicin—bone cancer	0.00102	0.00102	CcSEcCtD
Gadoversetamide—Paraesthesia—Doxorubicin—bone cancer	0.00101	0.00101	CcSEcCtD
Gadoversetamide—Dyspnoea—Doxorubicin—bone cancer	0.001	0.001	CcSEcCtD
Gadoversetamide—Feeling abnormal—Epirubicin—bone cancer	0.001	0.001	CcSEcCtD
Gadoversetamide—Somnolence—Doxorubicin—bone cancer	0.001	0.001	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Epirubicin—bone cancer	0.000995	0.000995	CcSEcCtD
Gadoversetamide—Dyspepsia—Doxorubicin—bone cancer	0.000991	0.000991	CcSEcCtD
Gadoversetamide—Decreased appetite—Doxorubicin—bone cancer	0.000978	0.000978	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000972	0.000972	CcSEcCtD
Gadoversetamide—Fatigue—Doxorubicin—bone cancer	0.00097	0.00097	CcSEcCtD
Gadoversetamide—Urticaria—Epirubicin—bone cancer	0.000966	0.000966	CcSEcCtD
Gadoversetamide—Constipation—Doxorubicin—bone cancer	0.000963	0.000963	CcSEcCtD
Gadoversetamide—Pain—Doxorubicin—bone cancer	0.000963	0.000963	CcSEcCtD
Gadoversetamide—Abdominal pain—Epirubicin—bone cancer	0.000962	0.000962	CcSEcCtD
Gadoversetamide—Body temperature increased—Epirubicin—bone cancer	0.000962	0.000962	CcSEcCtD
Gadoversetamide—Hypersensitivity—Methotrexate—bone cancer	0.000958	0.000958	CcSEcCtD
Gadoversetamide—Asthenia—Methotrexate—bone cancer	0.000933	0.000933	CcSEcCtD
Gadoversetamide—Feeling abnormal—Doxorubicin—bone cancer	0.000928	0.000928	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Doxorubicin—bone cancer	0.00092	0.00092	CcSEcCtD
Gadoversetamide—Pruritus—Methotrexate—bone cancer	0.00092	0.00092	CcSEcCtD
Gadoversetamide—Hypersensitivity—Epirubicin—bone cancer	0.000896	0.000896	CcSEcCtD
Gadoversetamide—Urticaria—Doxorubicin—bone cancer	0.000894	0.000894	CcSEcCtD
Gadoversetamide—Abdominal pain—Doxorubicin—bone cancer	0.00089	0.00089	CcSEcCtD
Gadoversetamide—Body temperature increased—Doxorubicin—bone cancer	0.00089	0.00089	CcSEcCtD
Gadoversetamide—Diarrhoea—Methotrexate—bone cancer	0.000889	0.000889	CcSEcCtD
Gadoversetamide—Asthenia—Epirubicin—bone cancer	0.000873	0.000873	CcSEcCtD
Gadoversetamide—Pruritus—Epirubicin—bone cancer	0.000861	0.000861	CcSEcCtD
Gadoversetamide—Dizziness—Methotrexate—bone cancer	0.00086	0.00086	CcSEcCtD
Gadoversetamide—Diarrhoea—Epirubicin—bone cancer	0.000832	0.000832	CcSEcCtD
Gadoversetamide—Hypersensitivity—Doxorubicin—bone cancer	0.000829	0.000829	CcSEcCtD
Gadoversetamide—Vomiting—Methotrexate—bone cancer	0.000826	0.000826	CcSEcCtD
Gadoversetamide—Rash—Methotrexate—bone cancer	0.00082	0.00082	CcSEcCtD
Gadoversetamide—Dermatitis—Methotrexate—bone cancer	0.000819	0.000819	CcSEcCtD
Gadoversetamide—Headache—Methotrexate—bone cancer	0.000814	0.000814	CcSEcCtD
Gadoversetamide—Asthenia—Doxorubicin—bone cancer	0.000808	0.000808	CcSEcCtD
Gadoversetamide—Dizziness—Epirubicin—bone cancer	0.000804	0.000804	CcSEcCtD
Gadoversetamide—Pruritus—Doxorubicin—bone cancer	0.000796	0.000796	CcSEcCtD
Gadoversetamide—Vomiting—Epirubicin—bone cancer	0.000773	0.000773	CcSEcCtD
Gadoversetamide—Nausea—Methotrexate—bone cancer	0.000772	0.000772	CcSEcCtD
Gadoversetamide—Diarrhoea—Doxorubicin—bone cancer	0.00077	0.00077	CcSEcCtD
Gadoversetamide—Rash—Epirubicin—bone cancer	0.000767	0.000767	CcSEcCtD
Gadoversetamide—Dermatitis—Epirubicin—bone cancer	0.000766	0.000766	CcSEcCtD
Gadoversetamide—Headache—Epirubicin—bone cancer	0.000762	0.000762	CcSEcCtD
Gadoversetamide—Dizziness—Doxorubicin—bone cancer	0.000744	0.000744	CcSEcCtD
Gadoversetamide—Nausea—Epirubicin—bone cancer	0.000723	0.000723	CcSEcCtD
Gadoversetamide—Vomiting—Doxorubicin—bone cancer	0.000716	0.000716	CcSEcCtD
Gadoversetamide—Rash—Doxorubicin—bone cancer	0.00071	0.00071	CcSEcCtD
Gadoversetamide—Dermatitis—Doxorubicin—bone cancer	0.000709	0.000709	CcSEcCtD
Gadoversetamide—Headache—Doxorubicin—bone cancer	0.000705	0.000705	CcSEcCtD
Gadoversetamide—Nausea—Doxorubicin—bone cancer	0.000669	0.000669	CcSEcCtD
